Events Partner Content Interstitial Lung Disease (ILD) Drug Development Summit Industry Led Conference on Fibrosing ILDs
News BMS swoops on Forbius, snaring another immuno-oncology playe... With the ink barely dry on a deal to develop Dragonfly’s lead cancer immunotherapy, Bristol-Myers Squibb’s business development team has agreed to buy Canadian biotech Forbius
Views & Analysis The promising future of RNA RNA technology-based therapeutics are a new and novel way to treat diseases.
News BMS begins Harvard fibrosis stem cell research collaboration R&D link-up with Harvard Fibrosis Network
News Pulmonary fibrosis drug developer Avalyn files IPO Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
